Interstitial Cystitis
3
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 3 programs with unclassified modality
Competitive Landscape
4 companies ranked by most advanced pipeline stage
MicroGenDXTX - Lubbock
1 programPolymerase Chain Reaction and Next-Generation DNA SequencingN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Ironwood PharmaceuticalsIW-3300 rectal foam
Tevafremanezumab
MediciNovaMN-001 BID
MicroGenDXPolymerase Chain Reaction and Next-Generation DNA Sequencing
Clinical Trials (4)
Total enrollment: 296 patients across 4 trials
A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
Start: Mar 2023Est. completion: Feb 2025
Phase 2Terminated
A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome
Start: Oct 2020Est. completion: Feb 20220
Phase 2Withdrawn
Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis
Start: May 2005Est. completion: Oct 2006296 patients
Phase 2Completed
Assessment of Urinary Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) Technology in the Evaluation and Management of Females With Chronic Bladder Pain and Cystitis-like Symptoms
Start: Feb 2022Est. completion: Dec 2023
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space